Breaking news on gout
Clinical Trial Demonstrates That Rilonacept Significantly Reduces Gout Flares published
Mon, 09 Jan 2012 00:00:00 PST
A phase II clinical trial found that rilonacept, an inhibitor of the protein interleukin-1 (IL-1), significantly reduced acute gout flares that occur when initiating uric acid-lowering therapy...
Gout Flares - Rilonacept Effective, According To Clinical Trial published
Fri, 06 Jan 2012 10:00:00 PST
According to a phase II clinical trial, the drug rilonacept, which inhibits the protein interleukin-1 (IL-1), substantially reduces acute gout flares that occur at the start of uric acid-reducing therapy and is noted to be generally well tolerated with no serious infections or serious adverse events occurring in relation to the treatment...
Regeneron Announces FDA Acceptance Of ARCALYST® (rilonacept) Supplemental Biologics License Application For Review published
Sat, 26 Nov 2011 01:00:00 PST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's supplemental Biologics License Application (sBLA) for ARCALYST Injection for Subcutaneous Use for the prevention of gout flares in patients initiating uric acid-lowering therapy...
Preventing Gout Flare Ups In Patients With Renal Impairment - Dosing Guidance published
Wed, 09 Nov 2011 05:00:00 PST
Results from a new pharmacokinetic (PK) study presented at the annual meeting of the American College of Rheumatology (ACR) provide new evidence-based guidance for healthcare providers on using colchicine for gout flare prophylaxis in the presence of renal impairment...
Gout Cases Missed By Traditional Tests Often Detected By CT Scans published
Mon, 07 Nov 2011 01:00:00 PST
X-ray images known as CT scans can help confirm gout in patients who are suspected of having the painful condition but receive negative results from traditional tests, a Mayo Clinic study has found. The type of CT scan analyzed, dual-energy computed tomography, is also valuable for diagnosing people who cannot be tested with the typical method of drawing fluid from joints, researchers found...
American College Of Rheumatology 2011 Annual Meeting: Presentations By NYU Langone Experts published
Mon, 07 Nov 2011 00:00:00 PST
Experts from NYU Langone Medical Center will present new research findings and clinical insight into the treatment of rheumatic and bone diseases in a variety of presentations at the American College of Rheumatology (ACR) 2011 Annual Scientific Meeting in Chicago, November 5-9, 2011...
Unsuitable Footwear Linked To Foot Impairment And Disability In Gout Patients published
Tue, 04 Oct 2011 00:00:00 PST
New research shows that use of poor footwear is common among patients with gout. According to the study published in Arthritis Care & Research, a peer-reviewed journal of the American College of Rheumatology (ACR), gout patients who make poor footwear choices experienced higher foot-related pain, impairment and disability...
Pegloticase, Alternative Treatment For Chronic Gout Shows Greater Improvement In Symptoms published
Wed, 17 Aug 2011 09:00:00 PST
According to a study in the August 17 issue of JAMA, patients with severe, chronic gout who took pegloticase for 6 months as an alternative to conventional gout treatment that some patients may not respond to, showed greater improvements of uric acid levels as well as physical function and quality of life...
New Drug Aids Gout Patients Not Helped By Standard Treatments published
Wed, 17 Aug 2011 01:00:00 PST
Injections of pegloticase, a modified porcine enzyme, can produce significant and sustained clinical improvements in 2 out of 5 patients with chronic gout that is resistant to conventional therapies, researchers report in the August 17, 2011, issue of JAMA...
Pegloticase Helps Patients With Severe, Chronic Gout published
Tue, 16 Aug 2011 15:00:00 PST
Individuals with severe, chronic gout who have not responded to conventional treatment may benefit from six-months' worth of pegloticase treatment. Researchers from Duke University Medical Center, Durham, N.C., reported in JAMA (Journal of the American Medical Association) that individuals experienced better levels of uric acid as well as physical function, quality of life, and less pain...
Increase In Obesity And Hypertension Are Likely Contributors To The Increase In Gout Prevalence In US Over Last 2 Decades published
Fri, 29 Jul 2011 01:00:00 PST
A new study shows the prevalence of gout in the U.S. has risen over the last twenty years and now affects 8.3 million (4%) Americans. Prevalence of increased uric acid levels (hyperuricemia) also rose, affecting 43.3 million (21%) adults in the U.S...
Got The Gout? Self Reported Cases Show Increase In Prevalence published
Thu, 28 Jul 2011 12:00:00 PST
Eight million Americans, almost 6% of men and 2% of women have got the gout, a painful affliction in which uric acid crystals are deposited in the joints. In a self reported survey, the prevalence of gout continues to climb along with rates of related conditions such as hypertension and metabolic syndrome, reaching 3.9% in 2008, according to a new study released this week...
Lower Doses Of Anti-Gout Drug Recommended published
Sat, 04 Jun 2011 19:00:00 PST
Health professionals should ensure they are prescribing correct doses of colchicine, a treatment for acute gout, after three elderly patients were hospitalised within a fortnight, doctors at St Vincent's Hospital in Sydney say in a letter published in the Medical Journal of Australia...
BioCryst Presents New Analyses Of BCX4208 Phase 2 Studies In Patients With Gout At The Annual European Congress Of Rheumatology published
Fri, 27 May 2011 09:00:00 PST
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today presented positive data from its two completed, randomized, double-blind, placebo-controlled Phase 2 studies of BCX4208 in patients with gout at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in London, U.K...
The True Burden Of Gout And Promising New Treatments published
Fri, 27 May 2011 02:00:00 PST
A pan-European study of 755 gout patients found that prevalence of self-reported gout was highest in the UK (2.2%) and lowest in France (0.76%)...
Additional Results From A Phase 2b Study Of Lesinurad In Combination With Allopurinol published
Thu, 26 May 2011 08:00:00 PST
Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that additional positive clinical and preclinical results from its development program of lesinurad, the Company's lead product candidate for the treatment of hyperuricemia and gout, were presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in London, UK...
Got The Gout? Novartis Sees Positive Results From Ilaris Treatment published
Wed, 25 May 2011 11:00:00 PST
Novartis is happy with results of new testing that supports approval of gout, or gouty arthritis treatment which is already in the review pipeline according to a new release this week by the Swiss/New York pharmaceutical giant. It is proving very successful in reducing patients' pain and limiting the risk of new attacks...
New Survey Reveals Most Americans Unaware Of Gout Risk Factors, In The Dark About Connection To Diabetes, Kidney Disease, And Cardiac Problems published
Thu, 19 May 2011 08:00:00 PST
A new survey from the nonprofit Gout & Uric Acid Education Society (GUAES) highlights an alarming awareness gap among Americans regarding the risk factors for gout, a chronic, potentially disabling form of arthritis which now affects an estimated 8.3 million Americans¹...
Teijin Pharma Expands Global Market For TMX-67 (febuxostat) - Turkey, Mexico, Caribbean, Middle East And North Africa published
Mon, 18 Apr 2011 03:00:00 PST
Teijin Pharma Limited, the core company of the Teijin Group's medical and pharmaceutical business, announced today that it has recently signed exclusive distributorship agreements with licensees in Turkey, Mexico and the Caribbean and Middle East and North African (MENA) regions for the expanded global marketing of TMX-67 (febuxostat), a novel drug developed by Teijin Pharma fo...
Seniors Group Asks Medicare Part-D Plans To Provide Affordable Gout Medication For Patients published
Fri, 25 Feb 2011 02:00:00 PST
As part of the 60 Plus Association's "Keeping Seniors Safe" project, the organization's chairman, Jim Martin, recently sent letters to the CEOs of five Part-D Medicare plans, urging them to provide accessible colchicine-based medications to gout patients after untested and potentially harmful options were removed from the marketplace as part of an important Food and Drug Admini...
TMX-67 (Febuxostat) Approved In Japan - Teijin-Developed Novel Drug For Chronic Management Of Hyperuricemia published
Mon, 24 Jan 2011 00:00:00 PST
Teijin Pharma Limited, the core company of the Teijin Group's medical and pharmaceutical business, announced today that Japan's Ministry of Health, Labour and Welfare approved TMX-67 (febuxostat), Teijin Pharma's novel drug for treating hyperuricemia, on January 21...
Uric Acid May Increase Likelihood Of Severe Osteoarthritis published
Wed, 19 Jan 2011 01:00:00 PST
The amount of uric acid in one's joints may increase the likelihood of severe osteoarthritis, the most common form of arthritis worldwide, according to researchers at Duke University Medical Center. Osteoarthritis is a debilitating joint degeneration for which no drug has been proven to slow or halt its progression...
By 2019, The Acute Gout Drug Market Will Triple In Size While The Chronic Gout Drug Market Will Reach $1.83 Billion published
Fri, 10 Dec 2010 06:00:00 PST
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that by 2019 the acute gout drug market will triple in size to $117 million and the chronic gout drug market will reach $1.83 billion...
TreatmentTrends®: European Gout Study Highlights Current Treatment Patterns And Unmet Need For New Gout Therapies Among Rheumatologists published
Thu, 09 Dec 2010 05:00:00 PST
BioTrends Research Group, Inc. finds that although Allopurinol remains the gold standard uric acid lowering (UAL) therapy for gout in the European Union (EU), Teijin Pharma/Ipsen/Menarini's Adenuric (currently available in France, Germany and the United Kingdom) has already achieved significant market penetration...
TreatmentTrends®: Gout Study Highlights Differences In Clinical Management Of Gout Between Primary Care Physicians And Rheumatologists published
Wed, 24 Nov 2010 03:00:00 PST
BioTrends Research Group, Inc. is pleased to announce the recent publication of a syndicated report, TreatmentTrends®: Gout. This biannual report provides a comprehensive market overview of current and future treatment trends in gout based on a primary research study fielded among 60 primary care physicians (PCPs) and 123 rheumatologists in the U.S...
)
|
|
